DE69628287D1 - Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten - Google Patents

Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten

Info

Publication number
DE69628287D1
DE69628287D1 DE69628287T DE69628287T DE69628287D1 DE 69628287 D1 DE69628287 D1 DE 69628287D1 DE 69628287 T DE69628287 T DE 69628287T DE 69628287 T DE69628287 T DE 69628287T DE 69628287 D1 DE69628287 D1 DE 69628287D1
Authority
DE
Germany
Prior art keywords
rar
retinoid
multiselective
agents
damaged skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69628287T
Other languages
English (en)
Other versions
DE69628287T2 (de
Inventor
Findlay Bryce
Seymour Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE69628287D1 publication Critical patent/DE69628287D1/de
Publication of DE69628287T2 publication Critical patent/DE69628287T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69628287T 1995-03-31 1996-03-19 Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten Expired - Lifetime DE69628287T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US414242 1995-03-31
US08/414,242 US5807900A (en) 1995-03-31 1995-03-31 Method for identifying compounds having increased activity for the repair of skin photodamage
PCT/EP1996/001176 WO1996030009A2 (en) 1995-03-31 1996-03-19 Compositions for treatment of photodamaged skin comprising an rar-alpha antagonist and a multi-selective retinoid

Publications (2)

Publication Number Publication Date
DE69628287D1 true DE69628287D1 (de) 2003-06-26
DE69628287T2 DE69628287T2 (de) 2004-04-08

Family

ID=23640589

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69628287T Expired - Lifetime DE69628287T2 (de) 1995-03-31 1996-03-19 Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten

Country Status (9)

Country Link
US (1) US5807900A (de)
EP (1) EP0817625B1 (de)
AT (1) ATE240725T1 (de)
AU (1) AU5146096A (de)
DE (1) DE69628287T2 (de)
DK (1) DK0817625T3 (de)
ES (1) ES2201175T3 (de)
PT (1) PT817625E (de)
WO (1) WO1996030009A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753627B1 (fr) * 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
FR2755011B1 (fr) * 1996-10-31 1998-11-20 Cird Galderma Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles et/ou les dommages aigus induits par les rayonnements u.v.
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU6513399A (en) * 1998-10-14 2000-05-01 Regents Of The University Of Michigan, The Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid
DE19926779A1 (de) * 1999-06-11 2000-12-14 Basf Ag Verwendung von substituierten Vinyl-tetrahydronaphthalinen und Vinyl-benzotetrahydropyranen als Lichtschutzmittel
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
US6603012B2 (en) 2000-05-02 2003-08-05 Hoffmann-La Roche Inc. RAR selective retinoid agonists
EP1935869A1 (de) 2000-10-02 2008-06-25 F. Hoffmann-La Roche Ag Retinoide zur Behandlung von Emphysem
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
NZ607547A (en) 2010-09-01 2015-06-26 Univ Jefferson Composition and method for muscle repair and regeneration
WO2012076842A1 (en) * 2010-12-09 2012-06-14 University Of Durham Synthetic retinoids for control of cell differentiation
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
CA2906800A1 (en) * 2013-03-15 2014-09-18 Avisenna Cosmetics, Llc Topical compositions for reducing the effects of aging
WO2021064072A1 (en) 2019-10-02 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of retinoic acid receptor (rar) agonists for reversing, preventing, or delaying calcification of aortic valve

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
AU610587B2 (en) * 1987-04-06 1991-05-23 Daltex Medical Sciences, Inc. Treatment of aged skin with oral 13-cis-retinoic acid
US5075333A (en) * 1987-08-19 1991-12-24 Hoffmann-La Roche Inc. Tetrahydronaphthalene and indane compounds useful for reversing the photo-damage in sun-exposed skin
EP0600028B1 (de) * 1991-08-23 2001-11-07 The Salk Institute For Biological Studies Verwendung von selektiven liganden zur behandlung von hormonansprechenden krankheitzuständen
CZ282548B6 (cs) * 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
CA2093577C (en) * 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids

Also Published As

Publication number Publication date
EP0817625A2 (de) 1998-01-14
DK0817625T3 (da) 2003-09-15
DE69628287T2 (de) 2004-04-08
PT817625E (pt) 2003-10-31
WO1996030009A3 (en) 1997-01-03
AU5146096A (en) 1996-10-16
EP0817625B1 (de) 2003-05-21
ATE240725T1 (de) 2003-06-15
WO1996030009A2 (en) 1996-10-03
ES2201175T3 (es) 2004-03-16
US5807900A (en) 1998-09-15

Similar Documents

Publication Publication Date Title
DE69628287D1 (de) Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
BR9611137A (pt) Composições e métodos para distribuição bucal de agentes farmacêuticos
BR9909324A (pt) Composição acidificada para tratamento tópico de condições da pele e unha
NO970580D0 (no) Retinsyre-X-reseptorligander
ATE238058T1 (de) Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel
DE69521700D1 (de) Mittel und methoden zur behandlung von plaque-krankheiten
TR199901173T2 (xx) Canl�larda glutamat anormalli�inin tedavisi ve n�ronal aktivitenin d�zenlenmesi i�in y�ntemler ve NAALADase bile�imleri.
PT785948E (pt) Analogos do factor de crescimento de queratinocitos
PT865294E (pt) Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob
MA22491A1 (fr) Compositions en emulsions stabilisees pour conferer un bronzage artificiel a la peau humaine
ATE192731T1 (de) Retinoid trienverbindungen und verfahren
ES2162051T3 (es) Preparacion dermatologica para tratar queratosis actinicas.
DE69532239D1 (de) Verfahren und präparate für die prophylaxe und therapie von mit endotoxin verbundenen zuständen
PT788361E (pt) Novas composicoes a base de uma mistura sinergetica entre pelo menos um ligante de vdr e um retinoide
ES2106057T3 (es) Liberacion de agentes.
ATE289808T1 (de) Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben
GB2274777B (en) Synergistic combination of compounds having an antagonist effect on nk1 and on nk2 receptors
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE258802T1 (de) Verwendung von vitis vinifera extrakten phospholipid komplexen als antiatherosclerotische mitteln
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
ATE187157T1 (de) Trizyclische retinoidverbindungen verfahren zu ihrer herstellung und verwendung
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
ATE245998T1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
BRPI0417692A (pt) uso de uma composição, método de redução dos efeitos do estresse mediado psicologicamente na pele de um ser humano ou animal, composição, suplemento nutritivo, composição cosmética, e, método para identificar um composto capaz de reduzir os efeitos e método de produção de uma composição para a redução dos efeitos, do estresse mediado psicologicamente sobre a pele de um ser humano ou animal

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN